Commentary on "Relationship between miRNA-21, miRNA-155, and miRNA-182 expression and inflammatory factors in cerebrospinal fluid from patients with multiple sclerosis"

Clin Neurol Neurosurg. 2024 Jan:236:108054. doi: 10.1016/j.clineuro.2023.108054. Epub 2023 Nov 20.

Abstract

This letter provides insightful perspectives on multiple sclerosis (MS) biomarkers, building upon Behrouz Shademan et al.'s study on miRNA-21, miRNA-155, and miRNA-182 [1]. Beyond these miRNAs, we delve into recent advancements, highlighting promising biomarkers such as ELTD1, CHI3L1, and Fecal Lcn-2. ELTD1 exhibits potential for MS diagnosis, CHI3L1 correlates with disability aspects, and Fecal Lcn-2 serves as a sensitive indicator for gut dysbiosis. Our exploration underscores the evolving landscape of MS biomarker research, urging further investigation for integrating these new markers into diagnostic and monitoring strategies.

Keywords: Biomarkers; Cerebrospinal fluid; Diagnosis; Inflammatory factors; Multiple sclerosis.

Publication types

  • Letter
  • Comment

MeSH terms

  • Biomarkers / cerebrospinal fluid
  • Disabled Persons*
  • Humans
  • MicroRNAs* / genetics
  • MicroRNAs* / metabolism
  • Multiple Sclerosis* / diagnosis

Substances

  • Biomarkers
  • MicroRNAs
  • MIRN155 microRNA, human
  • Mirn182 microRNA, human
  • MIRN21 microRNA, human